Source: International Congress 2014 – Bronchodilators for asthma and COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
R. Buhl, E. Derom, G. Ferguson, F. Maltais, E. Pizzichini, J. Reid, H. Watz, L. Groenke, A. Hamilton, K. Tetzlaff, L. Korducki, H. Huisman, S. Waitere-Wijker, E. Bateman (Mainz, Grosshansdorf, Ingelheim, Tübingen, Germany; Ghent, Belgium; Livonia, Ridgefield, United States Of America; Québec, Burlington, Canada; Santa Catarina, Brazil; Dunedin, New Zealand; Alkmaar, Netherlands; Cape Town, South Africa). Once-daily tiotropium and olodaterol fixed-dose combination via the respimat improves outcomes vs mono-components in COPD in two 1-year studies. Eur Respir J 2014; 44: Suppl. 58, 1895

Member's Comments

No comment yet.

Related content which might interest you: Safety of once-daily tiotropium and olodaterol fixed-dose combination via the respimat in chronic obstructive pulmonary disease in two 1-year studies Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Once-daily QVA149 improves lung function and dyspnoea compared with tiotropium plus formoterol: The QUANTIFY study Source: International Congress 2014 – Asthma and COPD management Year: 2014 Lung function efficacy of olodaterol QD delivered via Respimat® vs placebo and formoterol BID in patients with COPD: Two 48-week studies Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013 Once-daily tiotropium respimat add-on to ICS±LABA improves control across asthma severities Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014 Symptomatic benefit of olodaterol QD delivered via Respimat® vs placebo and formoterol BID in patients with COPD: Combined analysis from two 48-week studies Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013 Safety of tiotropium and olodaterol fixed-dose combination for COPD in patients on β-blockers Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 Efficacy and tolerability of aclidinium bromide/formoterol fumarate fixed-dose combination in patients with COPD: A 1-year study Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 48-week administration of olodaterol QD via Respimat® vs placebo and formoterol BID in patients with COPD: Pooled safety analysis Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 Once-daily QVA149 demonstrates superior outcomes in COPD patients previously treated with fixed-dose long-acting beta2-agonist/inhaled corticosteroid (LABA/ICS): The ILLUMINATE study Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 Comparison of indacaterol with tiotropium or once-daily dual long-acting bronchodilator therapy with roflumilast for severe COPD Source: International Congress 2014 – Markers Year: 2014 Once-daily tiotropium respimat add-on to at least ICS maintenance therapy reduces exacerbation risk in patients with uncontrolled symptomatic asthma Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 1-year efficacy and safety study of tiotropium respimat add-on to ICS in adolescent patients with symptomatic asthma Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014 Once-daily tiotropium Respimat add-on to at least ICS in adult patients with symptomatic asthma: Pooled safety analysis Source: International Congress 2014 – Asthma and COPD management Year: 2014 Efficacy of tiotropium and olodaterol fixed-dose combination in patients with COPD on β-blockers Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015 Comparison of the pharmacokinetics and pharmacodynamics of once daily tiotropium Respimat® and tiotropium HandiHaler® in COPD patients Source: Annual Congress 2013 –LAMA, LABA, ICS and their combinations for the treatment of asthma and COPD Year: 2013 LATE-BREAKING ABSTRACT: Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol/fluticasone combination (SFC) in patients with COPD: the LANTERN study Source: International Congress 2014 – Latest insights in airway diseases Year: 2014 Tiotropium respimat: Comparison of bronchodilator efficacy of 5 and 2.5 µg doses Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Efficacy of aclidinium/formoterol fixed-dose combination versus salmeterol/fluticasone in COPD Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015 Effects of 12 weeks of once-daily tiotropium and olodaterol fixed-dose combination on exercise endurance in patients with COPD Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 Lung function improvements with twice-daily aclidinium/formoterol fixed-dose combination in two 24-week studies in patients with COPD Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014